July 11 (Reuters) - Johnson & Johnson:
* JOHNSON & JOHNSON STRENGTHENS PIPELINE TO LEAD IN ATOPIC
DERMATITIS WITH THE COMPLETION OF THE ACQUISITION OF YELLOW
JERSEY THERAPEUTICS, GAINING OWNERSHIP OF NM26
Source text for Eikon:
Further company coverage: